| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 74.38 | 4.0% | 37.1% |
| Total Income | 74.38 | 4.0% | 37.1% |
| Expenditure | 67.65 | 0.9% | 0.7% |
| PBT | — | ||
| Net Profit | 0.62 | 132.1% | 103.9% |
| OPM | 9.05% | 2.78pp | 32.81pp |
| NPM | 0.83% | 3.53pp | 29.84pp |
| EPS | 0.00 | 100.0% | 100.0% |
Xeris Biopharma Reports Record Q3 2025 Revenue, Up 40% YoY
04 May 2026 · 4 May, 7:46 am
Summary
Xeris Biopharma Holdings, Inc. announced financial results for the third quarter ended September 30, 2025. Total product revenue increased 40% year-over-year to $74 million, driven by increased patient demand across all three products. Recorlev led the way, with revenue growing 109% to $37 million. The company is updating its 2025 total revenue guidance to $285-$290 million, which implies 42% growth at the midpoint compared to last year.
Key Highlights
- 1
Total product revenue increased by 40% year-over-year to $74 million in the third quarter of 2025.
- 2
Recorlev revenue grew by 109% year-over-year to $37 million in the third quarter of 2025.
- 3
The company is updating its full-year 2025 total revenue guidance to $285-$290 million.
- 4
Net income for the third quarter was $0.6 million, compared to a net loss of $15.7 million in the same period last year.
- 5
Adjusted EBITDA for the third quarter was $17.4 million, an improvement of $20.1 million compared to the third quarter of 2024.
- 6
Net loss for the nine months ending September 30, 2025, was $10.5 million or ($0.07) per share, compared to a net loss of $49.7 million or ($0.34) per share in the prior year period.
- 7
Adjusted EBITDA for the nine months ended September 30, 2025 was $34.3 million, an improvement of $41.4 million compared to the nine months ended September 30, 2024.
Management Comments
John Shannon
"We delivered another record-breaking quarter, driven by increased patient demand across all three products." "Total product revenue grew 40% year-over-year, highlighting the strength of our portfolio and the meaningful difference we’re making in the lives of patients and providers alike. Recorlev led the way, with revenue growing 109% to $37 million, further validating its significant growth potential." "Our year-to-date performance underscores the strength of our growth engine and the effectiveness of our strategic execution. With momentum continuing to build across the business, we are updating our 2025 total revenue guidance to $285-$290 million, which implies 42% growth at the midpoint compared to last year. As we progress through the final quarter, our focus remains on executing and investing in opportunities that will propel sustained growth into 2026 and beyond."
Informational and educational content only. Not investment advice.